"Expanding Access: Medicaid's Outcomes-Based Agreements for Sickle Cell Gene Therapies"
TL;DR Summary
The Centers for Medicare and Medicaid Services (CMS) will implement a program to reimburse expensive gene therapies for sickle cell disease based on patient outcomes, marking a significant shift in financing high-cost treatments. Starting next year, Medicaid programs will test outcomes-based agreements to pay for two FDA-approved gene therapies, with list prices of $2.2 million and $3.1 million, respectively.
- CMS details program to use outcomes-based agreements to pay for sickle cell gene therapies Endpoints News
- New FDA-approved sickle cell gene editing therapies offer hope for a pain-free life to patients – some living in Colorado Colorado Public Radio
- Biden-Harris Administration Announces Action to Increase Access to Sickle Cell Disease Treatments HHS.gov
- CMS: Cell and gene therapy model to focus first on sickle cell treatments FierceHealthcare
- Medicaid announces plan for expensive sickle cell gene therapies STAT
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
50%
117 → 59 words
Want the full story? Read the original article
Read on Endpoints News